On the heels of its acquisition by Catalent, Paragon Bioservices, the biologics contract development and manufacturing organization (CDMO), is forming a wide-ranging partnership in gene therapy manufacturing with Sarepta Therapeutics. The two companies will seek to establish additional dedicated facilities for manufacturing Sarepta’s gene therapy candidates.   Prior to the news, Catalent unveiled its intent to acquire Paragon for $1.2 billion. With the future support of Catalent and the op...